John Sarantopoulos

John Sarantopoulos

UNVERIFIED PROFILE

Are you John Sarantopoulos?   Register this Author

Register author
John Sarantopoulos

John Sarantopoulos

Publications by authors named "John Sarantopoulos"

Are you John Sarantopoulos?   Register this Author

55Publications

1501Reads

30Profile Views

Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.

J Clin Pharmacol 2019 Sep 15;59(9):1204-1215. Epub 2019 Apr 15.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1416DOI Listing
September 2019

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

J Pharmacol Exp Ther 2019 May 14;369(2):291-299. Epub 2019 Mar 14.

Medical Oncology Department, Ramón y Cajal Hospital, Madrid, Spain (E.G.); Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia (R.D.H., S.S.R.); Medical Oncology, Faculté de Médecine Lyon-Sud, Université Claude Bernard Lyon-1, Institute de Cancérologie des Hospices Civils de Lyon, Lyon, France (B.Y.); Medical Oncology Department, La Paz University Hospital, Autonoma University of Madrid (affiliated with CIBERONC-Instituto de Salud Carlos III), Madrid, Spain (J.F.B.); IQVIA, Kansas City, Missouri (H.G.); Institute for Drug Development, Mays Cancer Center at University of Texas, Health San Antonio, San Antonio, Texas (J.S.); Global Medicines Development, AstraZeneca, Cambridge, United Kingdom (H.M., K.S.); and Quantitative Clinical Pharmacology, Early Clinical Development IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom (M.J., K.V.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.118.255919DOI Listing
May 2019

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.

Invest New Drugs 2018 04 18;36(2):240-247. Epub 2017 Aug 18.

Quantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0498-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869873PMC
April 2018

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Invest New Drugs 2017 06 19;35(3):386-391. Epub 2017 Jan 19.

University of Texas Health Science Center San Antonio, 7979 Wurzbach Rd, MC8026, San Antonio, TX, 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0425-4DOI Listing
June 2017

A phase II study of REOLYSIN (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.

Cancer Chemother Pharmacol 2017 04 13;79(4):697-703. Epub 2017 Mar 13.

Division of Hematology/Oncology, Cancer Therapy and Research Center, University of Texas Health Science Center, 7979 Wurzbach Rd, San Antonio, TX, 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3260-6DOI Listing
April 2017

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.

Oncotarget 2016 Sep;7(37):59087-59097

Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.10824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312297PMC
September 2016

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.

Cancer 2016 Aug 18;122(16):2524-33. Epub 2016 May 18.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30073DOI Listing
August 2016

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.

Cancer Chemother Pharmacol 2015 Nov 3;76(5):1051-61. Epub 2015 Oct 3.

Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY, 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2878-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612322PMC
November 2015

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 13;32(6):1236-45. Epub 2014 Aug 13.

Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St. Louis, MO, 63110, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-014-0145-y
Publisher Site
http://dx.doi.org/10.1007/s10637-014-0145-yDOI Listing
December 2014

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Dec 11;74(6):1241-50. Epub 2014 Oct 11.

Institute for Drug Development, Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2602-xDOI Listing
December 2014

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.

Cancer Chemother Pharmacol 2014 Dec 12;74(6):1113-24. Epub 2014 Oct 12.

Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA, University of Texas Health Science Center San Antonio, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2572-zDOI Listing
December 2014

Predicting success in regulatory approval from Phase I results.

Cancer Chemother Pharmacol 2014 Nov 23;74(5):1099-103. Epub 2014 Sep 23.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-014-2596-4
Publisher Site
http://dx.doi.org/10.1007/s00280-014-2596-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489154PMC
November 2014

Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials.

Clin Genitourin Cancer 2014 Oct 4;12(5):359-65. Epub 2014 Feb 4.

Institute for Drug Development, Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492113PMC
October 2014

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 12;20(7):1900-9. Epub 2014 Feb 12.

Authors' Affiliations: Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; University of Leicester, Leicester, United Kingdom; University Hospital of Zürich, Zürich, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, New York; Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1710DOI Listing
April 2014

Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.

Clin Cancer Res 2013 Jul 15;19(14):3996-4007. Epub 2013 Apr 15.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2079DOI Listing
July 2013

Phase I study of GRN1005 in recurrent malignant glioma.

Clin Cancer Res 2013 Mar 24;19(6):1567-76. Epub 2013 Jan 24.

Center for Neuro-Oncology, Dana Farber/Brigham & Women's Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2481DOI Listing
March 2013

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

Mol Cancer Ther 2012 Feb 27;11(2):308-16. Epub 2011 Dec 27.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0566DOI Listing
February 2012

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2011 Dec 6;68(6):1565-73. Epub 2011 May 6.

University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1639-3DOI Listing
December 2011

The Pim kinases: new targets for drug development.

Curr Drug Targets 2011 Dec;12(14):2059-66

Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138945011798829447DOI Listing
December 2011

RANK ligand: effects of inhibition.

Curr Oncol Rep 2010 Mar;12(2):80-6

Cancer Therapy and Research Center, University of Texas Health Sciences Center, Zeller 4th Floor, 7979 Wurzbach Road, San Antonio, TX, 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-010-0088-1DOI Listing
March 2010

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.

Expert Opin Drug Metab Toxicol 2009 Dec;5(12):1607-14

The University of Texas Health Science Center, Institute for Drug Development at CTRC, Zeller's Building, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425250903451675DOI Listing
December 2009

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Clin Cancer Res 2009 Jun 19;15(11):3866-71. Epub 2009 May 19.

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2373DOI Listing
June 2009

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Clin Cancer Res 2008 Nov;14(21):7110-5

Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-08-0483DOI Listing
November 2008